IRWD Ironwood Pharmaceuticals Inc.

10.42
+0.03  (+0%)
Previous Close 10.39
Open 10.37
Price To Book -6.86
Market Cap 1,621,573,998
Shares 155,621,305
Volume 79,019
Short Ratio
Av. Daily Volume 1,446,029

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced August 21, 2017.
DUZALLO (LESINURAD AND ALLOPURINOL)
Hyperuricemia associated with gout
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Phase 3b data met all endpoints - June 18, 2019.
Linaclotide
Irritable Bowel Syndrome with Constipation (IBS-C)
Phase 2a data released April 2016. Development to be discontinued due to disappointing data
IW-9179
Gastroparesis
Phase 3 data due 2H 2020.
IW-3718
Gastroesophageal reflux disease (GERD)
No additional trials planned.
IW-1701
Achalasia
Phase 2 top-line data due 2H 2020.
MD-7246
Irritable Bowel Syndrome

Latest News

  1. 100 Summer lands WeWork ahead of tower's possible sale
  2. Hedge Funds Have Never Been This Bullish On Ironwood Pharmaceuticals, Inc. (IRWD)
  3. Company News For Jun 20, 2019
  4. Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients
  5. Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective
  6. Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
  7. See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
  8. Cambridge’s Ironwood Pharma moving HQ to downtown Boston
  9. Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston
  10. Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
  11. Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D
  12. Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report?
  13. Sarissa Capital Is Drawn to Ironwood Pharmaceuticals
  14. Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today
  15. 6 Positions the Vanguard Health Care Fund Continues to Increase
  16. Edited Transcript of IRWD earnings conference call or presentation 2-May-19 12:30pm GMT
  17. Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019
  18. Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%?